What is the current valuation of the Japan ophthalmic drugs market?

The market valuation was $2337.75 Million in 2024. Read More

What is the projected market size for the Japan ophthalmic drugs market by 2035?

The market is projected to reach $4590.0 Million by 2035. Read More

What is the expected CAGR for the Japan ophthalmic drugs market during the forecast period 2025 - 2035?

The expected CAGR is 6.33% during the forecast period 2025 - 2035. Read More

Which drug class had the highest valuation in the Japan ophthalmic drugs market in 2024?

Glaucoma drugs had the highest valuation at $600.0 Million to $1200.0 Million. Read More

What are the key players in the Japan ophthalmic drugs market?

Key players include Novartis, Allergan, Bausch Health, Regeneron Pharmaceuticals, Santen Pharmaceutical, Hoya Corporation, Akorn, and Ocular Therapeutix. Read More

What formulation type is expected to dominate the Japan ophthalmic drugs market?

Eye drops are expected to dominate, with a valuation range of $1200.0 Million to $2400.0 Million. Read More

What therapeutic application is projected to have significant growth in the Japan ophthalmic drugs market?

Cataracts and glaucoma are projected to have significant growth, each ranging from $600.0 Million to $1200.0 Million. Read More

What route of administration is most prevalent in the Japan ophthalmic drugs market?

Topical administration is most prevalent, with a valuation range of $1000.0 Million to $2000.0 Million. Read More

How do anti-inflammatory drugs perform in the Japan ophthalmic drugs market?

Anti-inflammatory drugs had a valuation range of $400.0 Million to $800.0 Million in 2024. Read More

What is the market outlook for artificial tears in the Japan ophthalmic drugs market?

The market for artificial tears is expected to grow, with a valuation range of $837.75 Million to $1590.0 Million. Read More

Japan Ophthalmic Drugs Market

ID: MRFR/Pharma/43559-HCR

200 Pages

Vikita Thakur

Last Updated: April 06, 2026

Japan Ophthalmic Drugs Market Research Report By Dosage Form (Eye Drops, Eye Ointments, Eye Solutions, Gels, Capsules Tablets, Others), By Product Type (Prescription Drug, OTC Drug), By Drug Class (Antibiotics, Anti-Inflammatory, Anti-Glaucoma, Others), By Indication (Glaucoma, Retinal Disorder, Dry Eye, Eye Allergy, Others) and By Distribution Channels (Hospital pharmacies, Drug stores, Online pharmacies, Others) - Growth & Industry Forecast 2025 To 2035

Japan Ophthalmic Drugs Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Drug Class (USD Million)
  1. 4.1.1 Anti-Inflammatory Drugs
  2. 4.1.2 Anti-Infective Drugs
  3. 4.1.3 Glaucoma Drugs
  4. 4.1.4 Ophthalmic Anesthetics
  5. 4.1.5 Artificial Tears
2. 4.2 Construction, BY Formulation Type (USD Million)
  1. 4.2.1 Liquid
  2. 4.2.2 Ointment
  3. 4.2.3 Eye Drops
  4. 4.2.4 Gel
  5. 4.2.5 Sustained Release
3. 4.3 Construction, BY Therapeutic Application (USD Million)
  1. 4.3.1 Allergic Conjunctivitis
  2. 4.3.2 Cataracts
  3. 4.3.3 Glaucoma
  4. 4.3.4 Dry Eye Syndrome
  5. 4.3.5 Intraocular Infections
4. 4.4 Construction, BY Route of Administration (USD Million)
  1. 4.4.1 Topical
  2. 4.4.2 Intraocular
  3. 4.4.3 Systemic
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Allergan (IE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bausch Health (CA)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Regeneron Pharmaceuticals (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Santen Pharmaceutical (JP)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Hoya Corporation (JP)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Akorn (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Ocular Therapeutix (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 JAPAN MARKET ANALYSIS BY DRUG CLASS
3. 6.3 JAPAN MARKET ANALYSIS BY FORMULATION TYPE
4. 6.4 JAPAN MARKET ANALYSIS BY THERAPEUTIC APPLICATION
5. 6.5 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY DRUG CLASS, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY DRUG CLASS, 2024 TO 2035 (USD Million)
14. 6.14 CONSTRUCTION, BY FORMULATION TYPE, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY FORMULATION TYPE, 2024 TO 2035 (USD Million)
16. 6.16 CONSTRUCTION, BY THERAPEUTIC APPLICATION, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY THERAPEUTIC APPLICATION, 2024 TO 2035 (USD Million)
18. 6.18 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
  2. 7.2.2 BY FORMULATION TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Million)
  4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Japan Construction Market Segmentation

Construction By Drug Class (USD Million, 2025-2035)

Anti-Inflammatory Drugs
Anti-Infective Drugs
Glaucoma Drugs
Ophthalmic Anesthetics
Artificial Tears

Construction By Formulation Type (USD Million, 2025-2035)

Liquid
Ointment
Eye Drops
Gel
Sustained Release

Construction By Therapeutic Application (USD Million, 2025-2035)

Allergic Conjunctivitis
Cataracts
Glaucoma
Dry Eye Syndrome
Intraocular Infections

Construction By Route of Administration (USD Million, 2025-2035)

Topical
Intraocular
Systemic

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”